DrugCombination product
Stenoparib clinical trials
Keep track of what changes. Save the stenoparib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 2
Allarity Therapeutics (3) · Eisai Limited (1) · VA Office of Research and Development (1) · The University of Texas Health Science Center at San Antonio (1)
Often tested with
Tested in the same studies.
Temozolomide (1) · Dovitinib (1) · Carboplatin (1) · Eribulin (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses stenoparib is read from its arms, and is right about nine times in ten.
Testing it · 6
- Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLCRecruitingPhase 1/2VA Office of Research and DevelopmentNCT06681220Written as Stenoparib/Temozolomide
- Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian CancerRecruitingPhase 2Allarity TherapeuticsNCT03878849Written as 2X-121
- Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid TumorsTerminatedPhase 1Allarity TherapeuticsNCT05571969Written as 2X-121 600 mg
- Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRPCompletedPhase 2Allarity TherapeuticsNCT03562832Written as PARP inhibitor 2X-121
- An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsCompletedPhase 1/2Eisai LimitedNCT01618136Written as E7449 alone
- Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related CancersWithdrawnPhase 1/2The University of Texas Health Science Center at San AntonioNCT02396433Written as E7449
Codes
What other systems call stenoparib · ClinicalTrials.gg INT000533
- MeSH (NLM) C000611123stenoparibOne source NLM
- UNII (FDA) 9X5A2QIA7C2X-121Confirmed FDA, NLM, Wikidata
- Wikidata Q27273339stenoparibConfirmed FDA, NLM, Wikidata
- DrugBank DB16063One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000611123 | stenoparib | One source NLM |
| UNII (FDA) | 9X5A2QIA7C | 2X-121 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27273339 | stenoparib | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB16063 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.